Evaluation of Angiopoietins and Cell-Derived Microparticles after Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 766-774

  Nomura, Shosaku ^a   Ishii, Kazuyoshi ^a   Inami, Norihito ^b   Kimura, Yutaka ^b   Uoshima, Nobuhiko ^c   Ishida, Hiroyuki ^c   Yoshihara, Takao ^c   Urase, Fumiaki ^d   Maeda, Yasuhiro ^d   Hayashi, Kunio ^e  

^a Kishiwada City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e Keihanna Hospital   (Japan)

Author keywords

Angiopoietin; endothelial cell derived microparticle; GVHD; sFas; stem cell transplantation

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOKINE; ETOPOSIDE; FAS LIGAND; FLUDARABINE; IFOSFAMIDE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MELPHALAN; RANIMUSTINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CELLS, CULTURED; CHILD; ENDOTHELIAL CELLS; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION;

EID: 44649201451     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.005     Document Type: Article

References (53)

1. Roberts M.M., To L.B., Gillis D., et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogenic bone marrow transplantation. Bone Marrow Transplant 12 (1993) 469-475
2. Juttner C.A., To L.B., Ho J., et al. Early lympho-hematopoietic recovery after autografting using peripheral blood stem cell in acute nonlymphoblastic leukemia. Transplant Proc 20 (1998) 40-42
3. Rowbottom A.W., Riches P.G., Downie C., and Hobbs J.R. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogenic bone marrow transplantation. Bone Marrow Transplant 12 (1993) 635-641
4. Testa S., Manna A., Porcellini A., et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 18 (1996) 383-388
5. Nishida T., Hamaguchi M., Hirabayashi N., et al. Intestinal thrombotic microangiopathy after allogenic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 33 (2004) 1143-1150
6. Krenger W., Hill G.R., and Ferrara J.L. Cytokine cascades in acute graft- versus-host disease. Transplantation 64 (1997) 553-558
7. Schmaltz C., Alpdogan O., Horndasch K.J., et al. Differential use of Fas ligand and perforin cytotoxic pathway by donor T-cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97 (2001) 2886-2895
8. Kagi D., Vignaux F., Ledermann B., et al. Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity. Science 265 (1994) 528-530
9. Lowin B., Hahne M., Mattmann C., and Tachopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370 (1994) 650-652
10. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
11. Das H., Imoto S., Murayama T., et al. Levels of soluble Fas and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol 104 (1999) 795-800
12. Takada S., Hatsumi N., Saito T., et al. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum. Am J Hematol 64 (2000) 133-136
13. Jaksch M., Uzunel M., Martinez Cangana G., Remberger M., and Mattsson J. Increased of immune transcript in patients with acute GVHD after allogenic stem cell transplantation. Bone Marrow Transplant 31 (2003) 183-190
14. Freyssinet J.M. Cellular microparticles: what are they bad or good for?. J Thromb Haemost 1 (2003) 1655-1662
15. Jy W., Horstmann L.L., Jimenez J.J., et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2 (2004) 1842-1851
16. Nomura S., Ishii K., Kanazawa S., et al. Significance of elevation in cell-derived microparticles after allogenic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant 36 (2005) 921-922
17. Dickinson A.M., Wang X.N., Sviland L., et al. I situ dissection of the graft-versus-host activities of cytotoxic T-cells specific for minor histocompatibility antigens. Nat Med 8 (2002) 410-414
18. Woywodt A., Scheer J., Hambach L., et al. Circulating endothelial cells as a marker of endothelial damage in allogenic hematopoietic stem cell transplantation. Blood 103 (2004) 3603-3605
19. Dumler J.S., Beschorner W.E., Farmer E.R., Gennaro K., Saral R., and Santos G.W. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 135 (1989) 1097-1103
20. Marelli-Berg F.M., James M.J., Dangerfield J., et al. Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood 103 (2004) 3111-3116
21. Ertault-Daneshpouy M., Leboeuf C., Lemann M., et al. Pericappillary hemorrhage as sriterion of serve human digestive graft-versus-host disease. Blood 103 (2004) 4681-4684
22. Kummer M., Lev A., Reiter Y., and Biedermann B.C. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic paptides: a mechanism of cell type-specific immune escape. J Immunol 174 (2005) 1947-1953
23. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87 (1996) 1161-1169
24. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
25. Papapetropoulos A., Garcia-Cardena G., Dengler T.J., et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79 (1999) 213-223
26. Kwak H.J., So J.N., Lee S.J., Kim I., and Koh G.Y. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 79 (1999) 213-223
27. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing anfiopoietin-1. Science 286 (1999) 2511-2514
28. Thurston G., Rudge J.S., Ioffe E., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 (2000) 460-463
29. Gamble J.R., Trew J., Trezise L., et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87 (2000) 603-607
30. Kim I., Moon S.O., Park S.K., Chae S.W., and Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-slectin expression. Circ Res 89 (2001) 477-479
31. Kim I., Oh J.L., Ryu Y.S., et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 16 (2002) 126-128
32. Pizurki L., Zhou Z., Glynos K., Roussos C., and Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 139 (2003) 329-336
33. Lim H.S., Blann A.D., Chong A.Y., Freestone B., and Lip G.Y.H. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes. Diabetes Care 27 (2004) 2918-2924
34. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfuntion and atherosclerosis. Atherosclerosis 180 (2005) 113-118
35. McCarter S.D., Lai P.F.H., Suen R.S., and Stewart D.J. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med 231 (2006) 985-991
36. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52 (1973) 2745-2756
37. Nomura S., Shouzu A., Omoto S., Nishikawa M., Iwasaka T., and Fukuhara S. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost 10 (2004) 205-215
38. Ferrara J.L., Cooke K.R., Pan L., and Krenger W. The immunopathophysiol of acute graft-versus-host-disease. Stem Cells 14 (1996) 473-489
39. Schots R., Kaufman L., Van Riet I., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogenic bone marrow transplantation. Leukemia 17 (2003) 1150-1156
40. Grimm J., Zeller W., and Zander A.R. Soluble interleukin-2 receptor serum levels after allogenic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 21 (1998) 29-32
41. Liem L.M., van Houwelingen H.C., and Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 66 (1998) 863-718
42. Min C.K., Lee M.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogenic hematopoietic ctem cell transplantation. Bone Marrow Transplant 28 (2001) 935-940
43. Lee W.Y., Baek K.H., Rhee E.J., et al. Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant 34 (2004) 89-94
44. Jimenez J.J., Jy W., Mauro L.M., Horstman L.L., Soderland C., and Ahn Y.S. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 123 (2003) 896-902
45. Pihusch V., Rank A., Steber R., et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 81 (2006) 1405-1409
46. Kanda Y., Tanaka Y., Shirakawa K., et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 22 (1998) 751-754
47. Kim I., Moon S., Park S.K., et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86 (2000) 24-29
48. Nomura S., Ishii K., Kanazawa S., et al. Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation. Transplant Immunol 15 (2006) 247-253
49. Li J.J., Huang Y.Q., Basch R., and Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85 (2001) 204-206
50. Nadar S., Blann A.D., and Lip G.Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effect of antihypertensive therapy. J Intern Med 256 (2004) 331-337
51. Nadar S., Blann A.D., and Lip G.Y. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin, and p-selectin levels in hypertensive patients. Am J Hypertens 19 (2006) 970-977
52. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
53. Fiedler U., Scharpfenecker M., Koidl S., et al. The tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Plade bodies. Blood 103 (2004) 4150-4156